Sezary syndrome (SS), an aggressive leukemia of mature T cells, is more complicated at a molecular level than ever suspected, according to research published by the Elenitoba-Johnson Lab in Nature Communications. With a poor prognosis and limited options for targeted therapies, fighting SS needs new treatment approaches. The team’s results uncover a previously unknown, complex genomic landscape of this cancer, which can be used to design new personalized drug regimens for SS patients based on their unique genetic makeup.
Read the Department of Communications news release.